Genetic and Preventive Services for Hereditary Breast and Ovarian Cancer in the Czech Republic

por Foretova, Lenka, Petrakova, Katarina, Palacova, Marketa, Kalabova, Renata, Navratilova, Marie, Lukesova, Miroslava, Vasickova, Petra, Machackova, Eva, Kleibl, Zdenek, Pohlreich, Petr
Publicado 2006

Biomarker Dynamics and Long-Term Treatment Outcomes in Breast Cancer Patients with Residual Cancer Burden after Neoadjuvant Therapy

por Holanek, Milos, Selingerova, Iveta, Fabian, Pavel, Coufal, Oldrich, Zapletal, Ondrej, Petrakova, Katarina, Kazda, Tomas, Hrstka, Roman, Poprach, Alexandr, Zvarikova, Maria, Bilek, Ondrej, Svoboda, Marek
Publicado 2022

nextMONARCH Phase 2 randomized clinical trial: overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with endocrine-refractory HR + , HE...

por Hamilton, Erika, Cortes, Javier, Ozyilkan, Ozgur, Chen, Shin-Cheh, Petrakova, Katarina, Manikhas, Aleksey, Jerusalem, Guy, Hegg, Roberto, Huober, Jens, Zhang, Wei, Chen, Yanyun, Martin, Miguel
Publicado 2022

Neoadjuvant Chemotherapy of Triple-Negative Breast Cancer: Evaluation of Early Clinical Response, Pathological Complete Response Rates, and Addition of Platinum Salts Benefit Based...

por Holanek, Milos, Selingerova, Iveta, Bilek, Ondrej, Kazda, Tomas, Fabian, Pavel, Foretova, Lenka, Zvarikova, Maria, Obermannova, Radka, Kolouskova, Ivana, Coufal, Oldrich, Petrakova, Katarina, Svoboda, Marek, Poprach, Alexandr
Publicado 2021

Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2− advanced breast cancer in the randomized MONALEESA-2 trial

por O’Shaughnessy, Joyce, Petrakova, Katarina, Sonke, Gabe S., Conte, Pierfranco, Arteaga, Carlos L., Cameron, David A., Hart, Lowell L., Villanueva, Cristian, Jakobsen, Erik, Beck, Joseph T., Lindquist, Deborah, Souami, Farida, Mondal, Shoubhik, Germa, Caroline, Hortobagyi, Gabriel N.
Publicado 2017

Management Strategies for Hyperglycemia Associated with the α-Selective PI3K Inhibitor Alpelisib for the Treatment of Breast Cancer

por Tankova, Tsvetalina, Senkus, Elżbieta, Beloyartseva, Maria, Borštnar, Simona, Catrinoiu, Doina, Frolova, Mona, Hegmane, Alinta, Janež, Andrej, Krnić, Mladen, Lengyel, Zoltan, Marcou, Yiola, Mazilu, Laura, Mrinakova, Bela, Percik, Ruth, Petrakova, Katarina, Rubovszky, Gábor, Tokar, Margarita, Vrdoljak, Eduard
Publicado 2022

AMEERA-3: Randomized Phase II Study of Amcenestrant (Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Monotherapy in Estrogen Receptor–Positive, Human Epidermal...

por Tolaney, Sara M., Chan, Arlene, Petrakova, Katarina, Delaloge, Suzette, Campone, Mario, Iwata, Hiroji, Peddi, Parvin F., Kaufman, Peter A., De Kermadec, Elisabeth, Liu, Qianying, Cohen, Patrick, Paux, Gautier, Wang, Lei, Ternès, Nils, Boitier, Eric, Im, Seock-Ah
Publicado 2023

Everolimus Plus Exemestane in Postmenopausal Patients with HR(+) Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis

por Yardley, Denise A., Noguchi, Shinzaburo, Pritchard, Kathleen I., Burris, Howard A., Baselga, José, Gnant, Michael, Hortobagyi, Gabriel N., Campone, Mario, Pistilli, Barbara, Piccart, Martine, Melichar, Bohuslav, Petrakova, Katarina, Arena, Francis P., Erdkamp, Frans, Harb, Wael A., Feng, Wentao, Cahana, Ayelet, Taran, Tetiana, Lebwohl, David, Rugo, Hope S.
Publicado 2013

Erratum to: Everolimus Plus Exemestane in Postmenopausal Patients with HR(+) Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis

por Yardley, Denise A., Noguchi, Shinzaburo, Pritchard, Kathleen I., Burris, Howard A., Baselga, José, Gnant, Michael, Hortobagyi, Gabriel N., Campone, Mario, Pistilli, Barbara, Piccart, Martine, Melichar, Bohuslav, Petrakova, Katarina, Arena, Francis P., Erdkamp, Frans, Harb, Wael A., Feng, Wentao, Cahana, Ayelet, Taran, Tetiana, Lebwohl, David, Rugo, Hope S.
Publicado 2014

Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial

por Rugo, Hope S., Im, Seock-Ah, Cardoso, Fatima, Cortés, Javier, Curigliano, Giuseppe, Musolino, Antonino, Pegram, Mark D., Wright, Gail S., Saura, Cristina, Escrivá-de-Romaní, Santiago, De Laurentiis, Michelino, Levy, Christelle, Brown-Glaberman, Ursa, Ferrero, Jean-Marc, de Boer, Maaike, Kim, Sung-Bae, Petráková, Katarína, Yardley, Denise A., Freedman, Orit, Jakobsen, Erik H., Kaufman, Bella, Yerushalmi, Rinat, Fasching, Peter A., Nordstrom, Jeffrey L., Bonvini, Ezio, Koenig, Scott, Edlich, Sutton, Hong, Shengyan, Rock, Edwin P., Gradishar, William J.
Publicado 2021

Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial

por Rugo, Hope S., Im, Seock-Ah, Cardoso, Fatima, Cortes, Javier, Curigliano, Giuseppe, Musolino, Antonino, Pegram, Mark D., Bachelot, Thomas, Wright, Gail S., Saura, Cristina, Escrivá-de-Romaní, Santiago, De Laurentiis, Michelino, Schwartz, Gary N., Pluard, Timothy J., Ricci, Francesco, Gwin, William R., Levy, Christelle, Brown-Glaberman, Ursa, Ferrero, Jean-Marc, de Boer, Maaike, Kim, Sung-Bae, Petráková, Katarína, Yardley, Denise A., Freedman, Orit, Jakobsen, Erik H., Gal-Yam, Einav Nili, Yerushalmi, Rinat, Fasching, Peter A., Kaufman, Peter A., Ashley, Emily J., Perez-Olle, Raul, Hong, Shengyan, Rosales, Minori Koshiji, Gradishar, William J.
Publicado 2023